# Safety, Tolerability and PK/PD Study in Young Adult Patients With Childhood Onset Growth Hormone Deficiency (GHD).

> **NCT00778518** · PHASE2 · COMPLETED · sponsor: **Ambrx, Inc.** · enrollment: 36 (estimated)

## Conditions studied

- Growth Hormone Deficiency

## Interventions

- **DRUG:** ARX201
- **DRUG:** ARX201
- **DRUG:** ARX201

## Key facts

- **NCT ID:** NCT00778518
- **Lead sponsor:** Ambrx, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2009-10-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00778518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00778518, "Safety, Tolerability and PK/PD Study in Young Adult Patients With Childhood Onset Growth Hormone Deficiency (GHD).". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00778518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*